Guardant Health adds five epigenomic cancer-testing tools
Guardant Health, Inc. (NASDAQ: GH) expanded its Guardant360 Liquid blood test with five new epigenomic applications for breast and lung cancer treatment decisions. The additions use its InfinityAI platform and target an oncology business that generated $231.3 million in Q3 revenue. The company did not disclose pricing or reimbursement changes. Shares closed at $155.35 on Nov. 10, predating the announcement.
How this was made

The 30-second read
Why it matters
The announcement expands Guardant's test menu, potentially increasing test adoption and market share in oncology diagnostics.
Market read
First‑time product launch could drive short‑term stock interest and longer‑term revenue growth.
What to watch
Potential regulatory review timelines and payer acceptance could delay commercial impact
Background
Guardant Health (NASDAQ: GH) reported Q3 revenue of $231.3 M and a 58% increase in test volume, then unveiled five epigenomic applications for its Guardant360 test.
Ticker impact
Guardant Health announced five new epigenomic cancer‑testing tools expanding its Guardant360 liquid biopsy platform.
likely upward pressure as investors price in expanded product offering
First‑time disclosure of multiple new applications; no pricing disclosed but potential revenue uplift.
Market effects
enhances the competitive position of liquid‑biopsy providers and may prompt peers to accelerate test development
U.S. precision‑oncology market sees incremental growth potential
adds to global trend of expanding liquid‑biopsy capabilities
Counterpoint
Without disclosed pricing or reimbursement data, the new tools may not translate into immediate revenue, limiting upside
Key entities
- companyGuardant Health
U.S. precision oncology firm developing liquid biopsy tests

